We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-6.8%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$189M
AUM Growth
-$38.3M
Cap. Flow
-$6.44M
Cap. Flow %
-3.41%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$6.44M

Sector Composition

Rank Sector Weight
1 Healthcare 97.29%
2 Technology 2.03%
3 Communication Services 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
1
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$50.8M 26.9%
4,645,453
– –
NTLA icon
2
Intellia Therapeutics
NTLA
$1.49B
$46.2M 24.47%
1,615,321
-221,489
-12% -$6.44M
SYBX
3
DELISTED
Synlogic
SYBX
$37.7M 19.94%
176,798
– –
COGT icon
4
Cogent Biosciences
COGT
$6.65B
$34.6M 18.33%
840,384
– –
SPRO icon
5
Spero Therapeutics
SPRO
$67.7M
$14.5M 7.66%
1,376,968
– –
CBLK
6
DELISTED
Carbon Black, Inc. Common Stock
CBLK
$3.84M 2.03%
181,273
– –
SNAP icon
7
Snap
SNAP
$7.89B
$1.27M 0.67%
150,160
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q3 2018 Portfolio in Review

As of Q3 2018, Atlas Venture Associates IX held 7 positions worth $189M, down 17% from $227M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX withdrew a net $6.44M in Q3 2018, reducing 1 holding. Its largest reduction was Intellia Therapeutics, cutting an estimated $6.44M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Technology and Communication Services.

  • Atlas Venture Associates IX's biggest Q3 2018 reduction was Intellia Therapeutics, cutting an estimated $6.44M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $189M portfolio in Q3 2018.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q3 2018.
  • Atlas Venture Associates IX's portfolio value fell 17% quarter-over-quarter to $189M.

Based on Atlas Venture Associates IX's 13F filing for Q3 2018, filed 7 Nov 2018.